Immunotherapy study yields unexpectedly strong results for lung cancer patients

A terminal cancer patient receives Keytruda drug.
(Image credit: John Moore/Getty Images)

Researchers in Chicago presented new data Monday that has big implications for lung cancer patients. A clinical trial discovered that pairing immunotherapy drugs with standard chemotherapy could significantly increase survival rates in lung cancer patients, Stat reports.

A trial study called Keynote-189 found that newly diagnosed lung cancer patients were 51 percent more likely to be alive in a year if they underwent a regimen that combined Keytruda, an immunotherapy drug by the pharmaceutical company Merck, with standard chemotherapy, than if they received chemotherapy treatment alone. Patients with the combined treatment were also 48 percent less likely to have their cancer progress in that year.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Kimberly Alters

Kimberly Alters is the news editor at TheWeek.com. She is a graduate of the Medill School of Journalism at Northwestern University.